BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65)-specific agonist.BTB09089 induces TDAG8 expression and regulates cytokine production in T cells and macrophages.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:3.87 mg/mL (10 mM)

BTB09089 (0-18 μM; 30 min) significantly increases the accumulation of cAMP in HEK293 cells transiently expressing hTDAG8 and mTDAG8, but does not exhibit a notable increase in control HEK293 cells. BTB09089 does not enhance the accumulation of cAMP in HEK293 cells expressing hGPR4 or the accumulation of inositol phosphates in HEK293 cells expressing hOGR1.[1]
BTB09089 (0-18 μM; 30 min) significantly enhances the accumulation of cAMP in a dose-dependent manner at pH 7.0-7.9, but not at pH 6.5.[1]
BTB09089 (1-5 μM; 20 h) dose-dependently inhibits the production of IL-2 in WT mouse splenocytes, but does not inhibit IL-2 production in TDAG8 KO mice and does not affect cell viability.[1]
BTB09089 (1-5 μM; 18 h) inhibits the production of TNF-α and IL-6 stimulated by LPS, while enhancing the production of IL-10 in peritoneal exudate cells (TG-PEC) induced by LPS stimulation with sulfated ester.[1]

BTB09089 (5-20 μM, 8 μL; i.c.v.; administered 6 hours prior to MCAO) reduces cerebral ischemia-reperfusion injury in rats.[2]